For the first time, the company introduced Zhang Qiang, a national leader, as the chief scientist of Jianfeng Pharmaceutical.
Release time:
2022-07-24
News from our newspaper # In early February, Dr. Zhang Qiang, a national leader and former researcher at the Karolinska Institute in Sweden, officially joined Spike as the chief scientist of Spike Pharmaceutical. This is the first time that Jianfeng has introduced national leading talents, and it is also the first time that Wucheng District has introduced national leading talents by enterprises.
national leading talents, that is, those selected into the national "tens of millions of talents project", can focus on the national development strategic objectives, in national key innovation projects, key disciplines and key laboratories, central enterprises and state-owned commercial financial institutions, and various parks dominated by high-tech industrial development zones, To achieve breakthrough in key technologies, develop high-tech industries, and drive strategic scientists and leading talents in emerging disciplines. Dr. Zhang Qiang, who was introduced by the company this time, was born in 1981 . After completing his bachelor's and master's studies at Jilin Agricultural University and Beijing Jiaotong University, he studied for a doctor's degree in life science at the Karolinska Institute in Sweden, which ranks fifth in the world for medical majors. After graduation, he conducted postdoctoral research and served as a researcher in the institute. Dr. Zhang has technical expertise in cell culture, cell transfection, cell proliferation assay, pharmaceutical pharmacology, protein structure simulation, structure-activity relationship (SAR) , etc., and has more than ten years of small molecule anti-tumor drug research and development experience, and has rich experience in drug screening and development. After joining Jianfeng Pharmaceutical, he will use his technical expertise to be responsible for the establishment of drug screening platforms and research on drug mechanisms, cell testing, and pharmacology research.
Continuously introducing high-end talents and optimizing the peak talent structure have always been the direction of the company's talent strategy. Xiang Chongping, deputy general manager of the group company, said that the introduction of national leading talents is an important achievement of the company's human resources work. Taking this as an opportunity, the company will further strengthen the introduction of talents, continuously optimize the talent management and use mechanism, and give foreign talents the space and stage to fully display their talents, so as to attract more high-end talents to join the peak; at the same time, it will also strengthen the training of internal talents, promote their faster growth, promote the continuous optimization of the company's talent team, and provide greater impetus for the innovation and development of enterprises.
(Reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page